 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-naïve Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Steven Flamm1, David Wyles2, Armen Asatryan3, Stanley Wang3, David Mutimer4, Jurgen Rockstroh5, Yves Horsmans6, Paul Y Kwo7, Ola Weiland8, Erica Villa9, Jeong Heo10, Edward Gane11, Stephen Ryder12, Tania Welzel13, Teresa I Ng3, Sandra S Lovell3, Preethi Krishnan3, Sarah Kopecky-Bromberg3, Roger Trinh3, Federico J Mensa3
1Northwestern Feinberg School of Medicine, Chicago, IL, USA; 2Denver Health Medical Center, Denver, CO, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit, Birmingham, UK; 5Universitätsklinikum Bonn, Bonn, Germany; 6Université Catholique de Louvain, Brussels, Belgium; 7Stanford University Division of Gastroenterology and Hepatology, Palo Alto, CA USA; 8Karolinska University Hospital Huddinge at Karolinska Institutet, Stockholm, Sweden; 9University of Modena and Reggio Emilia, Modena, Italy; 10Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; 11Liver Unit, Auckland City Hospital, Auckland, New Zealand; 12Nottingham Digestive Diseases Centre and Biomedical Research Unit, Nottingham, UK; 13JW Goethe University Hospital, Frankfurt, Germany
|
| |
|
|
|
|
|
